OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

OpGen, Inc.

OpGen is involved in molecular microbiology focused on combating antimicrobial resistance (AMR).

OpGen

OpGen, Inc. | 3,633 followers on LinkedIn. Mission

We harness the power of molecular microbiology to develop diagnostic solutions that will optimize the treatment of life-threatening, drug resistant infections. We seek to dramatically transform patient care to guide antibiotic therapy selection and help improve antibiotic stewardship.

About

Headquartered in Rockville, Maryland, OpGen (NASDAQ:OPGN) is a precision medicine company harnessing the power of molecular diagnostics to help combat infectious disease.

Metric
Company Name	OpGen, Inc.
Symbol	OPGN
MSH ID	COM:OPGEN
Market	STOCKS
Sector	Healthcare
Industry	Medical - Diagnostics & Research
Country	US
Stage	Post-IPO Equity
Employee Count	85
Website	opgen.com
LinkedIn	opgen
Founders

Metric
Market Cap	4.02M
Enterprise Value
Monthly Web Traffic	1.51K
Web Traffic Growth	0.13
Valuation
Raised Capital	3M

Metric
Revenue	3.42M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-90.69K
EBITDA	-14.23M
Operating Income	-30.75M
Net Income	-32.67M
EPS	-41.47
Diluted EPS	-41.47
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.07
Operating Profit Margin	-5.98
EBITDA Margin	-4.16
Net Profit Margin	-8.76
Return on Equity	8.34
Return on Assets	-1.48
Return on Capital Employed	3.22

COM:OPGEN

OpGen

Last Close

1.81

22/11 19:36

Market Cap

4.02M

Beta: -

Volume Today

850

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.10
P/B Ratio	1.05
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	16.28
EV Multiple	0.86

Metric
Days Sales Outstanding	50.26
Days Payables Outstanding	115.16
Days Inventory Outstanding	152.55
Operating Cycle	202.80
Cash Conversion Cycle	87.64
Asset Turnover	1.82

Metric
Operating Cash Flow	-14.32M
Free Cash Flow	-15.12M
Cash Flow to Debt	-0.48
Operating Cash Flow/Sales	-2.90
Free Cash Flow Yield	-5.57

Metric
Cash & Equivalents
Accounts Receivable	39.12K
Inventory
Goodwill
Debt to Capitalization	8.80
Debt to Assets	0.69
Current Ratio	0.28
Quick Ratio	0.11

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.12
R&D to Revenue	1.94
SG&A to Revenue	2.93